UA108475C2 - Композиція інсуліну тривалої дії - Google Patents

Композиція інсуліну тривалої дії

Info

Publication number
UA108475C2
UA108475C2 UAA201202336A UAA201202336A UA108475C2 UA 108475 C2 UA108475 C2 UA 108475C2 UA A201202336 A UAA201202336 A UA A201202336A UA A201202336 A UAA201202336 A UA A201202336A UA 108475 C2 UA108475 C2 UA 108475C2
Authority
UA
Ukraine
Prior art keywords
long
acting insulin
insulin composition
insulin compound
composition
Prior art date
Application number
UAA201202336A
Other languages
English (en)
Russian (ru)
Inventor
Кеннетт Спрогеє
Фелікс Клеєманн
Ульріх Херзель
Сільвія Каден-Фагт
Торбен ЛЕССМАНН
Харальд РАУ
Томас ВЕГГЕ
Original Assignee
Санофі-Авентіс Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофі-Авентіс Дойчланд Гмбх filed Critical Санофі-Авентіс Дойчланд Гмбх
Publication of UA108475C2 publication Critical patent/UA108475C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Винахід стосується фармацевтичної композиції, що містить сполуку інсуліну в концентрації щонайменше 10 мг/мл, яка характеризується тим, що вона має фармакокінетичний профіль in vivo по суті без викиду сполуки інсуліну, при цьому сполука інсуліну повністю міститься в депо-препараті.
UAA201202336A 2009-07-31 2010-07-30 Композиція інсуліну тривалої дії UA108475C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09167017 2009-07-31
EP09179337 2009-12-15
EP09179827 2009-12-18
PCT/EP2010/061160 WO2011012719A1 (en) 2009-07-31 2010-07-30 Long acting insulin composition

Publications (1)

Publication Number Publication Date
UA108475C2 true UA108475C2 (uk) 2015-05-12

Family

ID=43033453

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201202336A UA108475C2 (uk) 2009-07-31 2010-07-30 Композиція інсуліну тривалої дії

Country Status (29)

Country Link
US (1) US9265723B2 (uk)
EP (1) EP2459171B1 (uk)
JP (1) JP5732053B2 (uk)
KR (1) KR101759499B1 (uk)
CN (1) CN102625695B (uk)
AU (1) AU2010277560B2 (uk)
BR (1) BR112012001988A2 (uk)
CA (1) CA2769540C (uk)
CL (1) CL2012000469A1 (uk)
CO (1) CO6491085A2 (uk)
CR (1) CR20120019A (uk)
DK (1) DK2459171T3 (uk)
EC (1) ECSP12011631A (uk)
ES (1) ES2636741T3 (uk)
GT (1) GT201200020A (uk)
IL (1) IL217613A (uk)
MA (1) MA33466B1 (uk)
MX (1) MX2012001141A (uk)
NI (1) NI201200013A (uk)
NZ (1) NZ597964A (uk)
PE (1) PE20121170A1 (uk)
PL (1) PL2459171T3 (uk)
PT (1) PT2459171T (uk)
RU (1) RU2556340C2 (uk)
SG (1) SG178195A1 (uk)
TN (1) TN2012000010A1 (uk)
UA (1) UA108475C2 (uk)
WO (1) WO2011012719A1 (uk)
ZA (1) ZA201200224B (uk)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06010782A (es) * 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
PL2459171T3 (pl) 2009-07-31 2017-11-30 Sanofi-Aventis Deutschland Gmbh Kompozycja insuliny o długim działaniu
AU2010277559B2 (en) 2009-07-31 2016-08-11 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
AU2012216648C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
RU2014126244A (ru) * 2011-11-28 2016-01-27 Фэйзбио Фармасьютикалз, Инк. Лекарственные средства, содержащие аминокислотные последовательности инсулина
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US12239822B2 (en) 2013-03-15 2025-03-04 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
EP2983697B1 (en) 2013-04-03 2018-10-31 Sanofi Treatment of diabetes mellitus by long acting formulations of insulins
WO2015095624A2 (en) 2013-12-18 2015-06-25 Windgap Medical, Inc. Drug mixing and delivery system and method
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
JP2020114861A (ja) * 2014-01-09 2020-07-30 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
US9895423B2 (en) * 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP7173953B2 (ja) * 2014-01-09 2022-11-16 サノフイ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN103830189A (zh) * 2014-03-04 2014-06-04 山东新时代药业有限公司 一种重组甘精胰岛素制剂及其制备方法
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
CN107205938A (zh) 2014-12-18 2017-09-26 温德加普医疗股份有限公司 用于溶解或增溶治疗剂的方法和组合物
CN105796508A (zh) * 2014-12-30 2016-07-27 江苏万邦生化医药股份有限公司 甘精胰岛素缓释微球、甘精胰岛素微球注射剂及其制备方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MX2018009938A (es) 2016-03-01 2019-03-14 Ascendis Pharma Bone Diseases As Profarmacos de hormona paratiroidea (pth).
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
EP3518961B1 (en) * 2016-09-29 2023-02-22 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
MA46428B1 (fr) 2016-09-29 2025-02-28 Ascendis Pharma Bone Diseases A/S Composés de pth à libération contrôlée
CN109789189B (zh) 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 控释pth化合物的剂量方案
US10869851B1 (en) * 2017-03-13 2020-12-22 The United States Government As Represented By The Secretary Of The Army Targeting NUR77 for mitigating perinatal neuroinflammation
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
US20220040099A1 (en) * 2017-12-06 2022-02-10 Adocia Injectable solution at ph 7 comprising at least a basal insulin which pi is comprised between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CA3129357A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化
US12435116B2 (en) 2019-10-16 2025-10-07 Clarence Hurt Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
KR102945259B1 (ko) * 2021-09-30 2026-03-27 주식회사 엘지화학 마이크로 캐리어, 세포 복합체 및 이를 포함하는 의료용 조성물, 미용 조성물, 의료 용품 및 미용 용품
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
KR100266912B1 (ko) 1992-02-28 2000-12-01 파라비 레이 조직접촉물질이며 방출조절운반체인 광중합성 생분해성 하이드로겔
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE19626762A1 (de) 1996-07-03 1998-01-08 Basf Ag Enzymatisch spaltbare Linker für Festphasensynthesen
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
JP3786832B2 (ja) 1998-01-07 2006-06-14 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 分解性のヘテロ二官能性ポリ（エチレングリコール）アクリレート及びそれから誘導されるゲル及び複合体
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
EP1117444A2 (en) 1998-10-09 2001-07-25 The University Of Michigan Hydrogels and water soluble polymeric carriers for drug delivery
JP2002531217A (ja) 1998-12-04 2002-09-24 チャンドラシェカー ピー． パサック， 生体適合性架橋ポリマー
ES2368988T3 (es) 1999-02-01 2011-11-24 Eidgenössische Technische Hochschule Zürich Bio-materiales formados por reacción de adición nucleófila a grupos insaturados conjugados.
PT1105409E (pt) 1999-05-17 2006-07-31 Conjuchem Inc Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
KR100698559B1 (ko) 1999-06-11 2007-03-21 넥타르 테라퓨틱스 에이엘, 코포레이션 키토산 및 폴리(에틸렌 글리콜) 또는 관련 폴리머로부터유래되는 하이드로겔
US6372813B1 (en) 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001055360A1 (en) 2000-01-28 2001-08-02 Infimed Therapeutics, Inc. Slow release protein polymers
US6884778B2 (en) 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP4841066B2 (ja) 2000-09-01 2011-12-21 ライスユニバーシティ 酸化窒素生成ヒドロゲル物質
US6537569B2 (en) 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
AU2002258913A1 (en) 2001-04-23 2002-11-05 Wisconsin Alumni Research Foundation Bifunctional-modified hydrogels
JP2004535401A (ja) * 2001-05-21 2004-11-25 ネクター セラピューティックス 化学的に改変されたインスリンの肺投与
EP1306127B2 (en) 2001-10-26 2011-09-07 OctoPlus PolyActive Sciences B.V. Method for the preparation of purified microparticles
US6960298B2 (en) 2001-12-10 2005-11-01 Nanogen, Inc. Mesoporous permeation layers for use on active electronic matrix devices
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
JP4527404B2 (ja) 2002-04-04 2010-08-18 エンゾン，インコーポレーテッド インドールのポリマー性アシル誘導体
DE10221457A1 (de) 2002-05-15 2003-11-27 Behr Gmbh & Co Wärmeübertrager und Verfahren zu seiner Herstellung
JP2005535604A (ja) 2002-06-03 2005-11-24 アルニス バイオサイエンシーズ， インコーポレイテッド 治療剤を含むポリマーナノ物品
CA2487077A1 (en) 2002-06-10 2003-12-18 Merck & Co., Inc. Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
TR201907313T4 (tr) 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
MXPA06010782A (es) * 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
EP1586334A1 (en) 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006038462A1 (ja) 2004-10-01 2006-04-13 Kyushu University, National University Corporation 新規ステロイド産生細胞
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20060115865A1 (en) 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US7407117B2 (en) 2004-10-28 2008-08-05 Meadwestvaco Calmar, Inc. Liquid sprayer assembly
JP2006163996A (ja) 2004-12-09 2006-06-22 Evolium Sas 行動履歴に基づくプッシュ型の情報提供システム
WO2006073396A1 (en) 2005-01-05 2006-07-13 Regents Of The University Of Minnesota Analgesic conjugates
KR100665672B1 (ko) 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CA2636957A1 (en) 2006-01-12 2007-07-19 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
DE602006007679D1 (de) 2006-03-31 2009-08-20 Sony Deutschland Gmbh Verfahren zur Herstellung eines vernetzten Polymer-Gels
CA2653200A1 (en) 2006-05-25 2007-12-06 The General Hospital Corporation Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
GB0619175D0 (en) 2006-09-29 2006-11-08 Univ Nottingham Polymer
EP2099845B1 (en) 2006-11-27 2020-12-23 Actamax Surgical Materials LLC Multi-functional polyalkylene oxides, hydrogels and tissue adhesives
JP2010519183A (ja) 2007-02-06 2010-06-03 インセプト エルエルシー 生理溶液の溶出のためのタンパク質の沈殿を用いる重合
US20080220047A1 (en) 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
WO2008116913A2 (en) 2007-03-28 2008-10-02 Novo Nordisk A/S Peptide compounds with transient biodegradable pegylation
PL2136850T3 (pl) 2007-04-13 2012-07-31 Kuros Biosurgery Ag Polimeryczny uszczelniacz tkankowy
WO2008132229A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
EP2164519A2 (en) 2007-06-08 2010-03-24 Ascendis Pharma AS Long-acting polymeric prodrugs of exendin
WO2009010428A1 (en) 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
CA2711455C (en) 2008-02-13 2016-06-07 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
AU2009241847B2 (en) 2008-04-28 2014-07-10 Zogenix, Inc. Novel formulations for treatment of migraine
HRP20161040T1 (hr) 2008-04-29 2016-12-16 Ascendis Pharma Growth Disorders Division A/S Pegilirani rekombinantni spojevi ljudskog hormona rasta
EP2403537A1 (en) 2009-03-05 2012-01-11 Ascendis Pharma A/S Interferon alpha carrier prodrugs
AU2010277559B2 (en) 2009-07-31 2016-08-11 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
PL2459171T3 (pl) 2009-07-31 2017-11-30 Sanofi-Aventis Deutschland Gmbh Kompozycja insuliny o długim działaniu
CN102573913B (zh) 2009-07-31 2014-06-18 阿森迪斯药物股份有限公司 可生物降解的基于聚乙二醇的水不溶性水凝胶
US8986609B2 (en) 2009-10-29 2015-03-24 Ascendis Pharma A/S Sterilization of biodegradable hydrogels
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Also Published As

Publication number Publication date
CL2012000469A1 (es) 2012-10-19
GT201200020A (es) 2014-09-10
EP2459171B1 (en) 2017-06-21
IL217613A (en) 2016-08-31
DK2459171T3 (en) 2017-09-25
JP5732053B2 (ja) 2015-06-10
RU2556340C2 (ru) 2015-07-10
ECSP12011631A (es) 2012-02-29
CA2769540C (en) 2017-08-15
TN2012000010A1 (en) 2013-09-19
NZ597964A (en) 2014-04-30
MA33466B1 (fr) 2012-07-03
CR20120019A (es) 2012-03-02
AU2010277560A1 (en) 2012-02-23
EP2459171A1 (en) 2012-06-06
ES2636741T3 (es) 2017-10-09
RU2012107487A (ru) 2013-09-10
MX2012001141A (es) 2012-03-29
JP2013500952A (ja) 2013-01-10
NI201200013A (es) 2012-05-29
SG178195A1 (en) 2012-03-29
CA2769540A1 (en) 2011-02-03
BR112012001988A2 (pt) 2017-05-09
KR101759499B1 (ko) 2017-07-19
WO2011012719A1 (en) 2011-02-03
CN102625695A (zh) 2012-08-01
PL2459171T3 (pl) 2017-11-30
US20120183616A1 (en) 2012-07-19
CN102625695B (zh) 2015-05-27
CO6491085A2 (es) 2012-07-31
AU2010277560B2 (en) 2014-12-11
PE20121170A1 (es) 2012-09-10
ZA201200224B (en) 2012-09-26
KR20120089261A (ko) 2012-08-09
PT2459171T (pt) 2017-08-16
US9265723B2 (en) 2016-02-23

Similar Documents

Publication Publication Date Title
UA108475C2 (uk) Композиція інсуліну тривалої дії
UA104134C2 (uk) Рідка композиція, яка містить антитіло високої концентрації
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
NZ599848A (en) Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
PH12016500606A1 (en) Insulin preparations containing methionine
MX2012004420A (es) Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.
MX2009005797A (es) Derivado de acido carboxilico.
TN2012000248A1 (en) Novel spiropiperidine compounds
SI2379511T1 (sl) Substituirani diketopiperazinski analogi za uporabo kot sredstva za dostavo zdravil
NZ609309A (en) Redox drug derivatives
MY159565A (en) Pharmaceutical composition comprising a glp-1 agonist and methionine
EA201270216A1 (ru) Фармацевтический состав
PT2080501E (pt) Solução de fármaco tendo um teor reduzido de oxigénio dissolvido, método de produção da mesma e unidade para conter a solução de fármaco tendo um teor reduzido de oxigénio dissolvido
UA105042C2 (uk) Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання
ZA201005994B (en) Aqueous pharmaceutical compositions containing borate-polyol complexes
HRP20160953T1 (hr) Vodeni farmaceutski sastavi koji sadrže komplekse borat-poliol
MX348654B (es) Composicion farmaceutica con biodisponibilidad mejorada para compuesto hidrofobico de alto punto de fusion.
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2007095631A3 (en) New drug delivery system for crossing the blood brain barrier
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
TN2012000516A1 (en) Stable ready to use injectable paracetamol formulation
EP2163249A4 (en) INFUSION SOLUTION FOR PERIPHERAL INTRAVENOUS ADMINISTRATION
WO2009037586A3 (en) Use of peptidic vasopressin receptor agonists
WO2009121946A3 (en) Process for the preparation of optically enriched clopidogrel
MX2011008239A (es) Composicion farmaceutica solida que contiene sulfamato de 6-oxo-6,7,8,9,10,11-hexahidrociclohepta[c]cromen-3-ilo y sus polimorfos.